CPT code 82030 denotes a quantitative cyclic adenosine monophosphate (cAMP) assay performed on plasma or urine. The assay aids in differentiating causes of altered calcium and vitamin D metabolism, notably in the workup of suspected hyperparathyroidism and vitamin D deficiency. As a specialized biochemical laboratory test, it is ordered by clinicians managing disorders of mineral metabolism, endocrinology teams, and inpatient services when biochemical clarification is required.

Key payers commonly involved in coverage for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for when the test is used, typical sites of service, and the operational implications for laboratories and ordering clinicians. The publication also covers billing considerations and common modifiers used with laboratory services (general overview), payment benchmarks and variability across major national payers, and policy developments that affect laboratory reimbursement and medical necessity review for specialized endocrine assays.

This summary targets laboratory managers, billing professionals, clinicians in endocrinology and primary care, and policy analysts seeking a concise national view of CPT code 82030, its clinical role, and payer coverage landscape.